• U. Klaassen
  • S. Seeber


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Miller AHarris JR (1991) Incidence and demographics: radiation risk. In: (eds) Breast diseases. 229–232Google Scholar
  2. 2.
    Nowak R (1994) Breast Cancer gene offers surprises. Science 265:1796–1799PubMedCrossRefGoogle Scholar
  3. 3.
    WHO (1981) Histological typing of breast tumors, 2nd (ed) International histological classification of tumors. GenevaGoogle Scholar
  4. 4.
    Schnürch HG, Lange C, Bender HG (1987) Vier histopathologische Differenzierungsgrade beim Mammakarzinom? Daten zur Empfehlung der UICC von 1987. Pathologe 10:39–42Google Scholar
  5. 5.
    Honig SFHarris JR (1996) Chemotherapy for metastatic disease. In: et al. (eds) Diseases of the Breast. 22:669–1344Google Scholar
  6. 6.
    Clark GMHarris JR (1996) The role of prognostic indicators in node-negative breast cancer Henderson IC. Chemotherapy for metastatic disease. In: (eds) Diseasis of the Breast. 461–486Google Scholar
  7. 7.
    Cocconi G et al. (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer 51:581–588PubMedCrossRefGoogle Scholar
  8. 8.
    Kardinal CG et al. (1983) Chemoendocrine therapy vs. chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study. Breast Cancer Res Treat 3:365–372PubMedCrossRefGoogle Scholar
  9. 9.
    Krook JE et al. (1985) Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast. Cancer Treat Rep 69:355–361PubMedGoogle Scholar
  10. 10.
    Cocconi G et al. (1985) Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma: A prospective, randomized study. Am J Clin Oncol 13:226–232CrossRefGoogle Scholar
  11. 11.
    Fields JN, Kuske RR, Perez CA et al. (1989) Inflammatory carcinoma of the breast: Treatment results on 107 patients. Int J Radiat Oncol Biol Phys 17:249–255PubMedCrossRefGoogle Scholar
  12. 12.
    Bonadonna G et al. (1990) In Adjuvant Therapy of Cancer VI. Proceedings of the Sixth International Conference on the Adjuvant Therapy of Cancer, Tucson, Arizona, Mar. 7–10, eds. Salmon SE, Saunders, Philadelphia, 169–173Google Scholar
  13. 13.
    Engelsmann E et al. (1987) Comparison of “classic CMF” with a three-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: An EORTC study (trial 10808). Proc 4th EORTC breast cancer working conferenceGoogle Scholar
  14. 14.
    Early Breast Cancer Trialists Collaborative Group (1992) Systemic treatment of Early Breast Cancer by hormonal, cytotoxic, or immune therapy. The Lancet 339:1–15,Google Scholar
  15. 14a.
    Early Breast Cancer Trialists Collaborative Group (1992) Systemic treatment of Early Breast Cancer by hormonal, cytotoxic, or immune therapy. The Lancet 339:71–85Google Scholar
  16. 14b.
    Early Breast Cancer Trialists Collaborative Group (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. The Lancet 348:1189–1196CrossRefGoogle Scholar
  17. 15.
    Carpenter JT et al. (1994) Five-Year Results of a Randomidzed Comparison of Cyclophasphamide, Doxorubicin (Adriamycin) and Fluorouracil (CAF) vs. Cyclophasphamide, Methotrexate an Fluorouracil (CMF) for node positive Breast Cancer. Proc Am Soc Clin Oncol 13:66Google Scholar
  18. 16.
    Gianni L, Munzone ECapri G ., et al (1995) Paclitaxel by 3-hour infusion in combination with bolus Doxorubicin in women with untreated metastatic breast cancer. High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol Vol 13:2688–2699PubMedGoogle Scholar
  19. 17.
    Bull JM et al. (1978) A randomized comparative trial of adriamycin versus metho-tretate in combination drug therapy. Cancer 41:1649–1657PubMedCrossRefGoogle Scholar
  20. 18.
    Smalley R, Carpenter J, Bartolucci A, Vogel CKrauss S, (1977) A comparison of cyclophosphamide, Adriamycin, 5-fluorouracil (CAF) an cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. Cancer 40:625–632PubMedCrossRefGoogle Scholar
  21. 19.
    Muss HB et al. (1978) Adriamycin versus methotretate in five-drug combination chemotherapy for advanced breast cancer. J Clin Oncol 7:231–239Google Scholar
  22. 20.
    Brunner KW, Harder FGreiner R ., et al (1988) Loco-regional recurence following operation for breast cancer: Prognostic factors and the consequences of therapie. Schweiz Med Wochensch 118:1976–1981, (in German)Google Scholar
  23. 21.
    Tormey DC et al. (1982) Dibromodulcitol and Adriamycin plus or minus tamoxifen in advanced breast cancer. Am J Clin Oncol 5:33–39PubMedGoogle Scholar
  24. 22.
    Aisner J et al. (1987) Chemotherapy versus chemoimmunotherapy (CAF v. CAF-VP v. CMF each ± MER) for metastatic carcinoma of the breast: A CALGB study. J Clin Oncol 5:1523–1533PubMedGoogle Scholar
  25. 23.
    Brincker H et al. (1984) A randomized study of CAF + TAM versus CMF + TAM in metastatic brast cancer. Proc Am Soc Clin Oncol 3:113Google Scholar
  26. 24.
    Kolaric K et al. (1984) CAP (Cyclophosphamide, Adriamycin, Platinum) vs. CMFVP (Cyclophosphamide, Methotrexate, 5-Fluorouracin, Vincristine, Prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. Cander Chemother Pharmacol 13:142,144,184Google Scholar
  27. 25.
    Wilke H, Klaassen UAchterrath W , et al. (1996) Phase I/II study with a weekly 24 hour infusion of 5-Fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 7:55–58PubMedCrossRefGoogle Scholar
  28. 26.
    Klaassen U, Wilke H et al. (1995) Phase I/II Study with Paclitaxel in combination with weekly high-dose 5-Fluorouracil/Folinic acid (Hb-FU/FA) in the treatment of metastatic breast cancer. Semin Oncol Vol 22 (Suppl 14) : 7–11Google Scholar
  29. 27.
    Nicholson D, Paul D et al. (1996) A phase II treal of Paclitaxel, 5-Fluorouracil % Leucovorin in metastatic breast cancer. Proc Am Soc Clin Oncol 15:102Google Scholar
  30. 28.
    Carter CL et al. (1989) Relation of tumor size, lymph node status and survival in 24740 patients. Cancer 63:181–187PubMedCrossRefGoogle Scholar
  31. 29.
    Bonadonna G (1996) Current and future trends in the multidisciplinary approach for high risk breast cancer. The experience of the Milan Cancer Institute. Eur J Cancer 32A:209–214PubMedCrossRefGoogle Scholar
  32. 30.
    Rose C, Theilade K, Boesen E et al. (1982) Treatment of advanced breast cancer with tamoxifen. Breast Cancer Treat 2:395CrossRefGoogle Scholar
  33. 31.
    Miller AAHoeffken K (1986) Pharmakokinetik hormoneller Substanzen 40–47, in: Aktuelle Aspekte der Hormontherapie, (ed)Google Scholar
  34. 32.
    Robustelli Delia Cuna G, Calciati A, Strada MRB, et al. (1978) High dose medroxyprogesterone acetate (MPA) treatment of metastatic carcinoma of the breast: A dose-response evaluation Tumori 64:143–149Google Scholar
  35. 33.
    Becher R, Miller AA, Hoeffken K (1989) High dose medroxyprogesterone acetate treatment in advanced breast cancer. Cancer 63:138–1943CrossRefGoogle Scholar
  36. 34.
    Henderson ICHarris JR (1991) Endocrine therapy of metastatic breast cancer. In Breast diseases, (eds): , 559–603Google Scholar
  37. 35.
    Freyberg ER, Bland KI (1994) Overview of the biological and management of ductal carcinoma in situ of the breast. Cancer 74:350–361CrossRefGoogle Scholar
  38. 36.
    Morrow M, Schmitt SJ, Harris JRHarris JR (1996) Ductal Carcinoma in situ. In: et al. (eds) Diseases of the Breast. JB Lippincott Company, 355–365Google Scholar
  39. 37.
    Morrow M, Schmitt SJHarris JR (1996) Lobulär Carzinoma in situ. In: et al. (eds) Breast diseases. JB Lippincott Company, 369–574Google Scholar
  40. 38.
    Recht A, Hayes DFHarris JR (1991) Local recurrence following mastectomy. In et al. (eds) Diseases of the Breast. JB Lippincott Company, 649–668Google Scholar
  41. 39.
    Bedwinek JM, Fineberg B, Lee J et al. (1981) Analysis of failures following local treatment of isolated local-regional recurence of breast cancer. Int J Radiât Oncol Biol Phys 7:581–585PubMedCrossRefGoogle Scholar
  42. 40.
    Stomper PC, Recht A, Berenberg AL et al. (1987) Mammographic detection of recurrent cancer in the irradiated breast. Am J Radiol 148:39–43Google Scholar
  43. 41.
    Aberizk W et al. (1986) The use of radiotherapy for treatment of isolated loco-regional recurrence of breast carcinoma after mastectomy. Cancer 58:1214–1218PubMedCrossRefGoogle Scholar
  44. 42.
    Deutsch M et al. (1986) Radiation therapy for local-regional recurrent breast cancer. Int J Radiat Oncol Biol Phys 12:2061–2065PubMedCrossRefGoogle Scholar
  45. 43.
    Danoff B et al. (1983) Locally recurrent breast carcinoma: The effect of adjuvant chemotherapy on prognosis. Radiology 147:849–852PubMedGoogle Scholar
  46. 44.
    Magno L et al. (1987) Analysis of prognostic factors in patients with isolated chest wall recurrence of breast cancer. Cancer 60:240–244PubMedCrossRefGoogle Scholar
  47. 45.
    Heller K, Rosen P, Schottenfeld D (1978) Male breast cancer: A clinicopathologic study of 97 cases. Ann Surg 188:60–65PubMedCrossRefGoogle Scholar
  48. 46.
    Bagley C et al. (1989) Aduvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 10:55–60CrossRefGoogle Scholar
  49. 47.
    Malkin D et al. (1990) Germ line p53 mutations in a familial syndrome breast cancer, sarcomas and other neoplasms. Science 250:1233–1338PubMedCrossRefGoogle Scholar
  50. 48.
    Brun B et al. (1988) Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer 61:1096–1103PubMedCrossRefGoogle Scholar
  51. 49.
    Schaefer P, Alberto P, Forni M et al. (1987) Surgery as part of a combined modality approach for inflammatory breast carcinoma. Cancer 59:1063–1067CrossRefGoogle Scholar
  52. 49.
    Schaefer P, Alberto P, Forni M et al. 5-Fluorouracil plus highdose acid CJDFU (FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 7:55–58,1996CrossRefGoogle Scholar
  53. 50.
    Thorns WW, McNeese MD, Fletcher GH et al. (1989) Multimodal treatment for inflammatory breast cancer. Biol Phys 17:739–745Google Scholar
  54. 51.
    Fowble BF (1989) Combined modality treatment of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 17:739–745CrossRefGoogle Scholar
  55. 52.
    Knight CD et al. (1986) Surgical considerations after chemotherapy and radiation therapy for inflammatory breast cancer. Surgery 99:385–390 (1986)PubMedGoogle Scholar
  56. 53.
    Osborne KC, Clark GM, Ravdin PMHarris JR (1996) Adjuvant Systemic Therapy of Primary Breast Cancer. In: et al. (eds) Diseases of the Breast. JB Lippincott Company, 548–578Google Scholar
  57. 54.
    Buzdar AU, Kau SW, Hortobagyi GN et al. (1992) Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorobicin -containing adjuvant therapy. Cancer 69:448PubMedCrossRefGoogle Scholar
  58. 55.
    Lück HJ, Dubois A et al. (1996) Epirubicin/paclitaxel versus epirubicin/cyclo-phosphamide in metastatic breast cancer. A phase III trial for first line treatment of MBC. Study protocol AGOGoogle Scholar
  59. 56.
    Klaassen U, Borquez DSeeber S ., et al (1997) A multicenter randomized study for the first line treatment of advanced breast cancer: Epirubicine/Ifosfamide versus Epirubicine/Vinorelbine Study protocolGoogle Scholar
  60. 57.
    Goldhirsch A, Wood WC, Senn HJ, Glick HJ, Gelber RDSenn HJ (1996) IX. Consensus Conference on Primary Treatment of Breast Cancer. In: et al. (eds) Recent Results in Cancer Research. Adjuvant Therapy of Breast cancer V. Springer Verlag, 326–335Google Scholar
  61. 58.
    Bozec I, Nabholtz JM, Dieras V et al. (1997) Docetaxel in combination with Doxorubicin and with cyclophosphamide as first line chemotherapy in metastatic breast cancer: high activity and absence of cardiotoxicity. Proc Am Soc Clin Oncol, Vol 16 (abstr. # 566)Google Scholar
  62. 59.
    Fisher B, Dignam I, Delillis A et al. (1997) The worth of chemotherapy and tamoxifen over tamoxifen alone in node-negative patients with ER + invasive breast Cancer: First results from NSABP B 20. Proc Am Soc Clin Oncol, Vol 16 (abstr # 1)Google Scholar
  63. 60.
    Valero V, Holmes FA, Walters RS et al. (1995) Phase II trial of docotaxel, a new, highly effective antinioplastic agent in the management of patients with anthracy-cline resistant metastatic breast cancer. J Clin Oncol 13:2886–2894PubMedGoogle Scholar
  64. 61.
    Nabholz JM, Felmon K, Bontenbach M, Spielmann M, Catimel G, Conte P, Klaassen U, Narner M, Bormeterre J, Fummlean P, Winograd B (1996) A multi-center randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858–1867Google Scholar
  65. 62.
    Costa SD, von Minckwitz G (1998) Empfehlungen zur adjuvanten Therapie des Mammakarzinoms — Bericht von der sechsten internationalen Konferenz zur adjuvanten Therapie des primären Mammakarzinoms, St. Gallen, 1998. Tumordiagnostik u Ther 19:1–4Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • U. Klaassen
  • S. Seeber

There are no affiliations available

Personalised recommendations